Esperion to cut work force 40%
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), developers of a new class of cholesterol-lowering drugs, announced a 40 percent work force reduction and said it would focus its marketing efforts more …
BlueWillow Biologics sees positive results from Phase 1 trial of anthrax vaccine
ANN ARBOR—BlueWillow Biologics Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine …
MMS launches pro bono work for rare disease research
CANTON TWP.—Officials at MMS Holdings Inc., a contract research organization for the pharmaceutical industry, announced a pro-bono support program to advance research for ultra-rare diseases. Within this program, MMS will …
Esperion boosts sales of cholesterol-busting drugs
ANN ARBOR—The pharmaceutical firm Esperion Therapeutics Inc. (Nasdaq: ESPR) reported a rise in sales of its novel cholesterol-reducing drugs in the second quarter ended June 30 but still posted a …
MMS launches new courses for clinical trial management
CANTON TWP.—Officials at MMS Holdings, the Canton Township-based contract pharmaceutical research firm, announced that the company’s MMS Academy has launched new courses in inspection readiness and clinical programming for clinical …
New CEO at GR’s Tetra Therapeutics
GRAND RAPIDS—Officials at Tetra Therapeutics, a pharma startup developing drugs to treat brain disorders associated with cognitive and memory deficits, announced that CEO Mark Gurney had retired effective June 30. …
Esperion names chief medical officer
ANN ARBOR—Officials at the Ann Arbor cholesterol drug developer Esperion Therapeutics Inc. (Nasdaq: ESPR) announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as chief medical officer, effective immediately. …
Esperion names new president, CEO
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced the appointment of Sheldon Koenig as president, CEO, and board member, effective immediately. He succeeds Tim Mayleben, whom company officials said “decided to …
Esperion loss grows as sales effort ramps up
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) reported a loss of $90.8 million or $3.50 a share in the first quarter ended March 31, vs. a loss of $78.2 million or …
Esperion secures $50M in financing
ANN ARBOR—Esperion Therapeutics (NASDAQ: ESPR), developers of a novel class of cholesterol-reducing drugs, announced that an investor group led by New York City-based Oberland Capital Management LLC agreed to provide …